{"created":"2023-06-19T10:43:19.194951+00:00","id":3540,"links":{},"metadata":{"_buckets":{"deposit":"39001a21-f563-4a3f-9db0-8fd10263a415"},"_deposit":{"created_by":11,"id":"3540","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"3540"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00003540","sets":["6:7:275:276"]},"author_link":["6858","7892","7890","7891","147"],"item_3_alternative_title_18":{"attribute_name":"その他の言語のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"HER2陽性乳癌に対してPertuzumabを用いた術前化学療法を施行した16例"},{"subitem_alternative_title":"HER2 ヨウセイ ニュウガン ニ タイシテ Pertuzumab オ モチイタ ジュツゼン カガク リョウホウ オ セコウシタ 16レイ"}]},"item_3_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-05-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"22","bibliographicPageStart":"17","bibliographicVolumeNumber":"33","bibliographic_titles":[{"bibliographic_title":"滋賀医科大学雑誌"}]}]},"item_3_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"阿部, 元"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"寺本, 敦子"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"竹井, 裕美子"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"米田, 光里"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"田中, 義人"}],"nameIdentifiers":[{}]}]},"item_3_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Pertuzumab is a molecular-targeted drug that binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2) and inhibits dimer formation. The combined use of pertuzumab and trastuzumab for HER2-positive breast cancer has been reported to significantly increase the rate of pathological complete response (pCR) compared to that with trastuzumab monotherapy. We reported the outcomes of HER2-positive breast cancer treated with neoadjuvant chemotherapy with pertuzumab. Sixteen patients with stages II–III HER2-positive breast cancer were treated with 4 cycles of docetaxel (75 mg/m2) with trastuzumab and pertuzumab, followed by 4 cycles of 5-fluorouracil (500 mg/m2), epirubicin (100 mg/m2), and cyclophosphamide (500 mg/m2). The participants were in the age range of 45–76 years; T1, T2 and T3 stages were reported in 2, 11, and 3 cases, respectively, and N0 and N1 stages were reported in 6 and 10 cases, respectively. Luminal HER2 and HER2-enriched subtypes were noted in 8 cases each. In all cases, scheduled chemotherapy was completely implemented. Grade 3, 2b, 1a and 1b histology were observed in 11, 3, 1, and 1 cases, respectively. The rate of pCR (ypT0/is + ypN0) was 69%, whereas the objective response rate was 94%. In 12 cases, breast-conserving surgery was undertaken, whereas 4 patients underwent total mastectomy. Pertuzumab did not cause any complications, including cardiac dysfunction.","subitem_description_type":"Abstract"},{"subitem_description":"PertuzumabはHER2の細胞外ドメインに結合し、ダイマー形成を阻害するである。種々の試験において、trastuzumab単独よりもPertuzumabを併用した方が病理学的完全奏効率(pCR)を有意に上昇すると報告されている。今回、我々はHER2陽性乳癌に対してPertuzumabを用いた術前化学療法を行った。16名のStageII～IIIのHER2陽性乳患者に、Pertuzumab、Trastuzumab、Docetaxel（75 mg/m2）4コース、その後にFEC100療法4コースを施行した。年齢は45～76歳で、T1、T2、T3はそれぞれ2例、11例、3例、N0、N1はそれぞれ6例、10例であった。Luminal HER2 type、HER2 enrich typeともに8例であった。すべての症例で予定された化学療法が完全施行できた。組織学的効果はGrade3、2b、1a、1bがそれぞれ11例、3例、1例、1例であった。pCR（ypT0/is + ypN0）率は69％で、奏功率は94%であった。Pertuzumabによる心機能障害等の副作用は認められなかった。","subitem_description_type":"Abstract"}]},"item_3_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Departmental Bulletin Paper","subitem_description_type":"Other"}]},"item_3_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.14999/1521.00012662","subitem_identifier_reg_type":"JaLC"}]},"item_3_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"滋賀医科大学雑誌編集委員会"}]},"item_3_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.14999/1521.00012662"}],"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"http://doi.org/10.14999/1521.00012662","subitem_relation_type_select":"DOI"}}]},"item_3_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"ABE, Hajime"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"TERAMOTO, Atsuko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TAKEI, Yumiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YONEDA, Kohri"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TANAKA, Yoshihito"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-05-07"}],"displaytype":"detail","filename":"jsums3301p017.pdf","filesize":[{"value":"551.3 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"jsums3301p017","url":"https://shiga-med.repo.nii.ac.jp/record/3540/files/jsums3301p017.pdf"},"version_id":"6b54eada-81be-4fca-a169-0acf664509a5"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"HER2陽性乳癌","subitem_subject_scheme":"Other"},{"subitem_subject":"Pertuzumab","subitem_subject_scheme":"Other"},{"subitem_subject":"術前化学療法","subitem_subject_scheme":"Other"},{"subitem_subject":"pCR","subitem_subject_scheme":"Other"},{"subitem_subject":"HER2-positive breast cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Pertuzumab","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Neoadjuvant chemotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"pCR","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Sixteen cases of HER2-positive Breast Cancer treated with Neoadjuvant Chemotherapy with Pertuzumab.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Sixteen cases of HER2-positive Breast Cancer treated with Neoadjuvant Chemotherapy with Pertuzumab."}]},"item_type_id":"3","owner":"11","path":["276"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-05-07"},"publish_date":"2020-05-07","publish_status":"0","recid":"3540","relation_version_is_last":true,"title":["Sixteen cases of HER2-positive Breast Cancer treated with Neoadjuvant Chemotherapy with Pertuzumab."],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-06-19T11:14:55.593278+00:00"}